The present invention relates to a process for preparing alectinib or a pharmaceutically acceptable salt thereof. The present invention also relates to 5 intermediate compounds which are useful in such process and to the preparation of such intermediate compounds. Alectinib is approved as the hydrochloride salt, which is the active ingredient of drug Alecensa® and is intended for oral administration in the form of capsule. It is an anaplastic lymphoma kinase (ALK) inhibitor indicated for the treatment of patients with non-small-cell lung cancer (NSCLC).
Alessandra Tolomelli, L.F. (2018). Process for the preparation of alectinib.
Process for the preparation of alectinib
Alessandra Tolomelli;Lucia Ferrazzano;Assunta De Nisi;Walter Cabri
2018
Abstract
The present invention relates to a process for preparing alectinib or a pharmaceutically acceptable salt thereof. The present invention also relates to 5 intermediate compounds which are useful in such process and to the preparation of such intermediate compounds. Alectinib is approved as the hydrochloride salt, which is the active ingredient of drug Alecensa® and is intended for oral administration in the form of capsule. It is an anaplastic lymphoma kinase (ALK) inhibitor indicated for the treatment of patients with non-small-cell lung cancer (NSCLC).File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
